- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02679950
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse
The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, which are characterized by yolk sac tumor (and AFP secreting) predominant disease.
Investigators seek to demonstrate the feasibility of obtaining tissue biopsies (either archived or new biopsy) and utilization of NGGS in studying the molecular and genetic relationships between GCT's (with a component of yolk sac tumor) at the time of diagnosis and GCT's at the time of late relapse. This study will also provide preliminary information on genetic alterations, which may be a hypothesis for generating another study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will examine two cohorts:
- The initial diagnosis only cohort will include 3 patients with GCT who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
- The late relapse cohort will include 3 patients with late relapse GCT who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin RPLND that was done at initial diagnosis and the other will come from the site of late relapse.
Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department.
One tube of blood will be collected from each subject during a routine clinical visit at baseline when a blood draw is already being done.
In summary, a total of 15 samples will be evaluated on this study. Consent for the use of tissue and blood collected for the purposes of this study will be obtained prior to any study procedures. Subjects who do not have adequate tissue samples available will be replaced.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Eligible patients will have:
- Germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis or a late relapsed GCT (for the purposes of this study, late relapse will be defined as relapse > 2 years from the initial treatment of GCT).
- Adequate tumor specimens available from the initial orchiectomy specimen or virgin retro-peritoneal lymph node dissection (RPLND).
- Adequate tumor specimens available from any site of recurrent disease for patients accrued in the "late relapse" cohort.
- Tumor specimens collected prior to start of chemotherapy in the "late relapse" cohort.
- Age > 18 years
- Willing to provide informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Initial diagnosis
The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department.
One prospective blood and one tissue sample will be collected from each patient in this cohort.
Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
|
DNA will be extracted from each sample and assayed.
|
Late relapse
The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse. Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department. |
DNA will be extracted from each sample and assayed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare genomic profiles of curable germ cell tumors with non curable germ cell tumors
Time Frame: 1 year
|
Collection of tissue and blood samples from 6 patients for genomic testing
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nasser Hanna, MD, Indiana University School of Medicine, Indiana University Simon Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IUSCC-0540
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Germ Cell and Embryonal
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; University of Southern... and other collaboratorsActive, not recruiting
-
National Cancer Institute, SlovakiaCompleted
-
Costantine AlbanyTesaro, Inc.WithdrawnGerm Cell Tumor
-
Hoosier Cancer Research NetworkMerck Sharp & Dohme LLCCompletedGerm Cell TumorsUnited States
-
Indiana University School of MedicineIndiana UniversityTerminatedGerm Cell TumorUnited States
-
University of SydneyDana-Farber Cancer Institute; University of Southern California; Cambridge University... and other collaboratorsRecruitingGerm Cell TumorAustralia, New Zealand, United States
-
Barts & The London NHS TrustUnknownGerm Cell TumourUnited Kingdom
-
N.N. Petrov National Medical Research Center of...RecruitingTesticular Germ Cell TumorRussian Federation
-
Royal Marsden NHS Foundation TrustUniversity College London (UCL) Cancer InstituteUnknownTesticular Germ Cell TumorUnited Kingdom
Clinical Trials on Next generation genome sequencing
-
Munich Leukemia LaboratoryIllumina, Inc.RecruitingLeukemia | Rare Diseases | Refractory Lymphoma | Hematologic Malignancy | Refractory Leukemia | Unknown Primary TumorsGermany
-
Asan Medical CenterRecruitingPancreatic Cancer | Chemotherapy Effect | Genetic ChangeKorea, Republic of
-
Imperial College London Diabetes CentreUnknownDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Maturity-onset Diabetes of the YoungUnited Arab Emirates
-
Qingyuan ZhanNot yet recruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingBiliary Tract Cancer (BTC)Taiwan
-
Konkuk University Medical CenterFoundation Medicine; Roche DiagnosticsRecruitingAdenocarcinoma of Lung | EGFR Activating MutationKorea, Republic of
-
Xiangya Hospital of Central South UniversityHunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaboratorsCompletedBladder Cancer | Urine | Diagnosis | BiomarkerChina
-
University Hospital HeidelbergFraunhofer Institute for Interfacial Engineering and Biotechnology; Dietmar...CompletedSepsis | Septic ShockGermany
-
Rothman Institute OrthopaedicsEnrolling by invitation
-
Huashan HospitalChildren's Hospital of Fudan University; Shanghai Jiao Tong University Affiliated...UnknownInfectious Disease | Next Generation SequencingChina